Fig. 1From: Anlotinib plus icotinib as a potential treatment option for EGFR-mutated advanced non-squamous non-small cell lung cancer with concurrent mutations: final analysis of the prospective phase 2, multicenter ALTER-L004 studyEfficacy of the combination of anlotinib + icotinib. Kaplan-Meier curves of PFS and OS in the ITT population (A, B) and cases with pathogenic concurrent mutations (C, D)Back to article page